首页> 外文期刊>Oncology Reviews >The diagnostic and predictive accuracy of thyroglobulin to TSH ratio and TSH to thyroglobulin ratio in detecting differentiated thyroid carcinoma in normothyroid patients with thyroid nodules: A retrospective cohort study and systematic review of the literature
【24h】

The diagnostic and predictive accuracy of thyroglobulin to TSH ratio and TSH to thyroglobulin ratio in detecting differentiated thyroid carcinoma in normothyroid patients with thyroid nodules: A retrospective cohort study and systematic review of the literature

机译:甲状腺素与TSH比甲状腺癌甲状腺结节患者分化甲状腺癌中TSOR球蛋白比的诊断和预测准确度:回顾性队列研究与文献系统综述

获取原文
           

摘要

The purpose of the present study is to examine the diagnostic and predictive accuracy of the thyroglobulin (Tg) to thyroid stimulating hormone (TSH) and TSH/Tg ratios in normothyroid patients with differentiated thyroid cancer (DTC). We conducted a retrospective cohort study evaluating the diagnostic accuracy of the serum Tg/TSH and TSH/Tg ratios in normothyroid patients with thyroid nodules. We also systematically searched the international literature using the Medline, Cochrane’s CENTRAL, Scopus, Clinicaltrials.gov, EMBASE, and Google Scholar databases for evidence concerning the diagnostic and predictive accuracy of these ratios. Overall, 374 patients were identified in our cohort study of whom 240 were treated for benign disease and 134 were treated for DTC. Significant differences were noted in the Tg/TSH and TSH/Tg values among cases with malignant and benign disease (P=0.020). However, the diagnostic ROC curve did not confirm these results (Tg/TSH=0.572 and TSH/Tg=0.428). After searching the international literature, we identified 8 studies. The majority of the included data reported significant differences among patients with benign/malignant disease and those with successful iodine therapy compared to those with disease relapse. However, the clinical relevance was clearer among studies that investigated the usefulness of these ratios in predicting recurrent disease. The findings of our study support that the Tg/TSH ratio increases in patients with DTC and can, thus, become useful in the future as a predictive marker of ablative 131I therapy success. However, given the significant variability of Tg its diagnostic accuracy remains to date minimal; thus, the actual cut-off value that can be used to discriminate cancer cases from benign disease has not been determined yet.
机译:本研究的目的是研究甲状腺蛋白(TG)对甲状腺刺激激素(TSH)和TSH / TG比率的甲状腺功能亢进患者的诊断和预测准确性,分化的甲状腺癌(DTC)。我们进行了一种回顾性队列研究,评估甲状腺结节术术术中血清TG / TSH和TSH / TG比率的诊断准确性。我们还系统地使用Medline,Cochrane的中央,Scopus,Clinicaltrials.gov,Embase和Google学者数据库来系统地搜索了国际文献,用于有关这些比率的诊断和预测准确性的证据。总体而言,在我们的队列研究中发现了374名患者,其中240名被良性疾病治疗,134名用于DTC。在恶性和良性疾病的情况下,TG / TSH和TSH / TG值中注意到显着差异(P = 0.020)。但是,诊断ROC曲线未确认这些结果(TG / TSH = 0.572和TSH / TG = 0.428)。在寻找国际文献之后,我们确定了8项研究。其中大多数数据报告患有良性/恶性疾病的患者的显着差异,与疾病复发的人相比,碘治疗成功的患者。然而,临床相关性在研究中更清楚地研究了这些比例在预测复发性疾病中的有用性。我们的研究表明,DTC患者的TG / TSH比率增加,因此,将来变得有用作为冻蚀131I治疗成功的预测标志。但是,鉴于TG的显着变化,其诊断精度仍有迄今为止的差异;因此,尚未确定可用于区分良性疾病的癌症病例的实际截止值。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号